食品伙伴網(wǎng)訊  2020年5月13日，應(yīng)歐盟委員會(huì)的要求，歐盟食品安全局（EFSA）營(yíng)養(yǎng)、新型食品和食品過(guò)敏原小組（NDA）就AstraGin作為新型食品的安全性發(fā)布意見(jiàn)。

 

　　據(jù)了解，AstraGi是一種從三七（Panax notoginseng）和黃芪（Astragalus membranaceus）中提取的植物提取物。申請(qǐng)人建議這種新型食品作為普通成年人（不包括孕婦）的食品補(bǔ)充劑，每日最高劑量為350毫克。部分原文報(bào)道如下：

 

　　The NF is a combination of an ethanol extract of the roots of A. membranaceus and a hot water extract of the roots of P. notoginseng. The NF contains 1.5–5% total saponins, 0.1–0.5% ginsenoside Rb1 and 0.01–0.1% astragaloside I. Both plants that are used to produce the NF have a long history of use, especially in traditional Chinese medicine. Information on the production process and the composition of the NF is sufficient and does not raise safety concerns. The applicant proposed to use the NF as a food supplement for the general adult population, excluding pregnant women, at a maximum daily amount of 350 mg. Taking into account these conditions of use, the Panel considers that the consumption of the NF is not nutritionally disadvantageous. The provided genotoxicity studies do not raise concerns for genotoxicity of the NF. based on the findings of a subchronic toxicity study, supported by a subacute toxicity study, the Panel identified the overall no observed adverse effect level （NOAEL） of the NF at 100 mg/kg body weight （bw） per day. By applying an uncertainty factor of 200, the Panel concludes that the NF is safe at an intake level of 0.5 mg/kg bw per day, corresponding to a maximum daily intake of 35 mg of the NF for the target population, i.e. adults excluding pregnant women.

 

　　本文由食品伙伴網(wǎng)食品資訊中心編輯，供網(wǎng)友參考，歡迎轉(zhuǎn)載，轉(zhuǎn)載請(qǐng)注明出處！有任何疑問(wèn)，請(qǐng)聯(lián)系news@foodmate.net。